Dr. Leonidas Tsiokas's lab focuses on understanding how mutations in specific genes affect kidney function, specifically in conditions like Autosomal Dominant Polycystic Kidney Disease (ADPKD). His team seeks to uncover the role of the Polycystin complex—a group of proteins involved in kidney cyst formation—by exploring its function as a type of receptor that interacts with signaling molecules. Their research could lead to new treatments for kidney diseases.

Dr. Rajagopal Ramesh's lab focuses on innovative cancer treatments using advanced drug delivery systems and immune modulation techniques. They explore how exosomes, small vesicles released by cells, can carry cancer medications directly to tumors to improve treatment effectiveness and reduce side effects. The lab's research also investigates ways to combine these treatments with immune checkpoint inhibitors to enhance the body’s immune response against lung cancer.

Jie Wu's lab at the University of Oklahoma focuses on developing new drugs that target the RET oncogene in cancers such as lung and thyroid cancer. The lab aims to create next-generation RET inhibitors that can effectively treat patients who have developed resistance to existing therapies. By optimizing novel compounds, they work towards providing better therapeutic options for patients with RET-positive tumors.